SCD

Oncology

12 drugs in development·6 companies·1 clinical trial

Drug Pipeline by Phase

Approved(4)

Drug	Company
CASGEVY	CRISPR Therapeutics AG (CRSP)
CASGEVY (exagamglogene autotemcel)	Editas Medicine, Inc. (EDIT)
oxbryta	Global Blood Therapeutics, Inc. (GBT)
PYRUKYND®	AGIOS PHARMACEUTICALS, INC. (AGIO)

Phase 3(3)

Drug	Company
crizanlizumab	Novartis AG (NVS)
Crizanlizumab	Novartis AG (NVS)
inclacumab	Global Blood Therapeutics, Inc. (GBT)

Phase 1(3)

Drug	Company
gbt601	Global Blood Therapeutics, Inc. (GBT)
reni-cel	Editas Medicine, Inc. (EDIT)
renizgamglogene autogedtemcel (reni-cel)	Editas Medicine, Inc. (EDIT)

Preclinical(1)

Drug	Company
In vivo HSC gene editing program for SCD and TDT	Editas Medicine, Inc. (EDIT)

Phase 2/Phase 3(1)

Drug	Company
ft-4202	Forma Therapeutics Holdings, Inc. (FMTX)

BioSniper tracks 12 drugs in development for SCD across 6 companies.

There are 1 clinical trial targeting SCD tracked by BioSniper.

Full trial data, competitive analysis, and AI-powered pipeline tracking.